NCT04267939 - ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 26, 2020

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions

Advanced Solid Tumors (Excluding Prostate Cancer)Ovarian Cancer

Interventions

DRUG

Elimusertib (BAY1895344)

Elimusertib will be administered in 28-day cycles.

DRUG

Niraparib

Niraparib will be administered in 28-day cycles.

Trial Locations (3)

Memorial Sloan-Kettering Cancer Center, New York

University of Texas MD Anderson Cancer Center, Houston

Dana-Farber Cancer Institute, Boston